353 related articles for article (PubMed ID: 29644451)
21. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
22. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Manceau C; Mourey L; Pouessel D; Ploussard G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
[TBL] [Abstract][Full Text] [Related]
23. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
24. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
25. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Gourdin T
Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
[TBL] [Abstract][Full Text] [Related]
26. Recent advances revolutionize treatment of metastatic prostate cancer.
Madan RA; Arlen PM
Future Oncol; 2013 Aug; 9(8):1133-44. PubMed ID: 23902245
[TBL] [Abstract][Full Text] [Related]
27. Advancing therapies in metastatic castration-resistant prostate cancer.
Baciarello G; Gizzi M; Fizazi K
Expert Opin Pharmacother; 2018 Nov; 19(16):1797-1804. PubMed ID: 30311804
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
29. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
Takahara K; Naiki T; Ito T; Nakane K; Koie T; Yasui T; Miyake H; Shiroki R
Int J Urol; 2022 Mar; 29(3):229-234. PubMed ID: 34863085
[TBL] [Abstract][Full Text] [Related]
30. A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.
Teoh JYC; Poon DMC; Lam D; Chan T; Chan MFT; Lee EKC; Law S; Chan K; Cheng NM; Lai KM; Leung CH; Ng CF
Clin Genitourin Cancer; 2019 Feb; 17(1):e203-e208. PubMed ID: 30454968
[TBL] [Abstract][Full Text] [Related]
31. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Ohlmann CH
Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
[TBL] [Abstract][Full Text] [Related]
32. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
33. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
34. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hormone-naïve metastatic prostate cancer.
Hamilou Z; Saad F; Fizazi K
Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
[TBL] [Abstract][Full Text] [Related]
36. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
37. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Caffo O; Veccia A; Kinspergher S; Maines F
Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
[TBL] [Abstract][Full Text] [Related]
38. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG
Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970
[TBL] [Abstract][Full Text] [Related]
39. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Nevedomskaya E; Baumgart SJ; Haendler B
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
